CASI Pharmaceuticals, Inc.
CASI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3,075 | $4,175 | $6,240 | $13,356 |
| % Growth | -26.3% | -33.1% | -53.3% | – |
| Cost of Goods Sold | $2,369 | $2,117 | $2,621 | $10,128 |
| Gross Profit | $706 | $2,058 | $3,619 | $3,228 |
| % Margin | 23% | 49.3% | 58% | 24.2% |
| R&D Expenses | $1,413 | $1,724 | $1,936 | $3,666 |
| G&A Expenses | $4,927 | $6,084 | $7,698 | $7,121 |
| SG&A Expenses | $9,537 | $11,044 | $11,921 | $11,918 |
| Sales & Mktg Exp. | $4,610 | $4,960 | $4,223 | $4,797 |
| Other Operating Expenses | $433 | $415 | $141 | $558 |
| Operating Expenses | $11,383 | $13,183 | $13,998 | $16,142 |
| Operating Income | -$10,677 | -$11,125 | -$10,379 | -$12,914 |
| % Margin | -347.2% | -266.5% | -166.3% | -96.7% |
| Other Income/Exp. Net | -$206 | -$76 | -$371 | -$1,456 |
| Pre-Tax Income | -$10,883 | -$11,201 | -$10,750 | -$14,370 |
| Tax Expense | $0 | $2,174 | $0 | $0 |
| Net Income | -$10,883 | -$13,375 | -$10,750 | -$14,370 |
| % Margin | -353.9% | -320.4% | -172.3% | -107.6% |
| EPS | -0.68 | -0.86 | -0.69 | -0.93 |
| % Growth | 20.9% | -24.6% | 25.8% | – |
| EPS Diluted | -0.68 | -0.86 | -0.69 | -0.93 |
| Weighted Avg Shares Out | 16,049 | 15,506 | 15,493 | 15,493 |
| Weighted Avg Shares Out Dil | 16,049 | 15,506 | 15,493 | 15,493 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $45 | $77 | $0 |
| Interest Expense | $195 | $244 | $197 | $0 |
| Depreciation & Amortization | $583 | $0 | $0 | $583 |
| EBITDA | -$10,105 | -$10,957 | -$10,553 | -$9,757 |
| % Margin | -328.6% | -262.4% | -169.1% | -73.1% |